ADM’s latest research into its proprietary probiotic strain Bifidobacterium lactis BPL1 (CECT 8145) has elucidated the probiotic strain’s mechanism of action. This refers to the specific biochemical interaction that explains its potential role in impacting biomarkers related to weight management and metabolic health.
With the evidence, ADM claims it can support partners in the dietary supplements and food and beverage sectors with the scientific understanding they need when considering current regulatory expectations for their claims and positioning, opening product development opportunities.
“The publication of this new research is the result of more than ten years of preclinical and clinical trials, demonstrating our commitment to using our scientific expertise to support innovations in the probiotic space”, said Daniel Ramón Vidal, ADM VP of R&D of the company’s Health & Wellness business.
“We’re excited to see how ADM can use this new evidence to support our partners in developing exciting new food, beverage and dietary supplement solutions.”
